drugset

drugset / Trial / NCT00316238

A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia

NCT00316238 ↗

Phase 2 Completed 160 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia

Timeline

Start: 2006-04
Primary completion: —
Completion: 2007-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olanzapine	Small molecule	—	Intramuscular

Indications